Serum Neurofilament Identifies Patients With Multiple Sclerosis With Severe Focal Axonal Damage in a 6-Year Longitudinal Cohort

BACKGROUND AND OBJECTIVES: Immunomodulatory therapies reduce the relapse rate but only marginally control disability progression in patients with MS. Although serum neurofilament light chain (sNfL) levels correlate best with acute signs of inflammation (e.g., relapses and gadolinium-enhancing [Gd+]...

Descripción completa

Detalles Bibliográficos
Autores principales: Steffen, Falk, Uphaus, Timo, Ripfel, Nina, Fleischer, Vinzenz, Schraad, Muriel, Gonzalez-Escamilla, Gabriel, Engel, Sinah, Groppa, Sergiu, Zipp, Frauke, Bittner, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679887/
https://www.ncbi.nlm.nih.gov/pubmed/36411080
http://dx.doi.org/10.1212/NXI.0000000000200055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679887/
https://www.ncbi.nlm.nih.gov/pubmed/36411080
http://dx.doi.org/10.1212/NXI.0000000000200055

Ejemplares similares